What is HC Wainwright’s Forecast for ORKA FY2024 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for Oruka Therapeutics in a research report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.24) per share for the year, down from their prior forecast of ($1.56). HC Wainwright currently has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

ORKA has been the subject of a number of other reports. Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. Wedbush restated an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Leerink Partnrs upgraded shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. TD Cowen started coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Finally, Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Stock Up 8.4 %

Shares of Oruka Therapeutics stock opened at $20.26 on Wednesday. The company’s fifty day simple moving average is $25.76. The company has a market cap of $709.08 million, a PE ratio of -3.24 and a beta of 0.87. Oruka Therapeutics has a 52 week low of $18.20 and a 52 week high of $53.88.

Institutional Trading of Oruka Therapeutics

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $343,000. The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $1,037,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics in the 3rd quarter worth $2,013,000. Janus Henderson Group PLC bought a new position in Oruka Therapeutics during the 3rd quarter worth about $5,840,000. Finally, Redmile Group LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at about $10,091,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.